210 related articles for article (PubMed ID: 35715140)
41. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.
Shurell E; Vergara-Lluri ME; Li Y; Crompton JG; Singh A; Bernthal N; Wu H; Eilber FC; Dry SM
Oncotarget; 2016 Nov; 7(45):72860-72867. PubMed ID: 27655679
[TBL] [Abstract][Full Text] [Related]
42. Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures.
Cheung LS; Chen L; Oke TF; Schaffer TB; Boudadi K; Ngo JT; Gross JM; Kemberling H; Diaz LA; Lipson E; Sidhom JW; Taube J; Anders R; Pardoll DM; Le DT; Meyer CF; Llosa N
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103354
[TBL] [Abstract][Full Text] [Related]
43. Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.
Suarez-Kelly LP; Baldi GG; Gronchi A
Expert Opin Pharmacother; 2019 Aug; 20(12):1503-1515. PubMed ID: 31136210
[No Abstract] [Full Text] [Related]
44. Soft tissue sarcomas: From a morphological to a molecular biological approach.
Oda Y; Yamamoto H; Kohashi K; Yamada Y; Iura K; Ishii T; Maekawa A; Bekki H
Pathol Int; 2017 Sep; 67(9):435-446. PubMed ID: 28759137
[TBL] [Abstract][Full Text] [Related]
45. Recent advances in the understanding and management of liposarcoma.
Haddox CL; Riedel RF
Fac Rev; 2021; 10():1. PubMed ID: 33659920
[TBL] [Abstract][Full Text] [Related]
46. Role of Immunotherapy in Sarcomas.
Dalal S; Shan KS; Thaw Dar NN; Hussein A; Ergle A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279265
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes.
Vargas AC; Maclean FM; Sioson L; Tran D; Bonar F; Mahar A; Cheah AL; Russell P; Grimison P; Richardson L; Gill AJ
PLoS One; 2020; 15(4):e0222551. PubMed ID: 32294103
[TBL] [Abstract][Full Text] [Related]
48. Current Landscape of Immunotherapy for Advanced Sarcoma.
Albarrán V; Villamayor ML; Pozas J; Chamorro J; Rosero DI; San Román M; Guerrero P; Pérez de Aguado P; Calvo JC; García de Quevedo C; González C; Vaz MÁ
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190214
[TBL] [Abstract][Full Text] [Related]
49. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
50. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
Martín-Broto J; Moura DS; Van Tine BA
Clin Cancer Res; 2020 Nov; 26(22):5801-5808. PubMed ID: 32601077
[TBL] [Abstract][Full Text] [Related]
51. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
Barretina J; Taylor BS; Banerji S; Ramos AH; Lagos-Quintana M; Decarolis PL; Shah K; Socci ND; Weir BA; Ho A; Chiang DY; Reva B; Mermel CH; Getz G; Antipin Y; Beroukhim R; Major JE; Hatton C; Nicoletti R; Hanna M; Sharpe T; Fennell TJ; Cibulskis K; Onofrio RC; Saito T; Shukla N; Lau C; Nelander S; Silver SJ; Sougnez C; Viale A; Winckler W; Maki RG; Garraway LA; Lash A; Greulich H; Root DE; Sellers WR; Schwartz GK; Antonescu CR; Lander ES; Varmus HE; Ladanyi M; Sander C; Meyerson M; Singer S
Nat Genet; 2010 Aug; 42(8):715-21. PubMed ID: 20601955
[TBL] [Abstract][Full Text] [Related]
52. Undifferentiated and dedifferentiated soft tissue neoplasms: Immunohistochemical surrogates for differential diagnosis.
Thway K; Fisher C
Semin Diagn Pathol; 2021 Nov; 38(6):170-186. PubMed ID: 34602314
[TBL] [Abstract][Full Text] [Related]
53. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas.
Dancsok AR; Gao D; Lee AF; Steigen SE; Blay JY; Thomas DM; Maki RG; Nielsen TO; Demicco EG
Oncoimmunology; 2020; 9(1):1747340. PubMed ID: 32313727
[TBL] [Abstract][Full Text] [Related]
54. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
Italiano A; Bellera C; D'Angelo S
J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
[TBL] [Abstract][Full Text] [Related]
55. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
56. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology.
Mertens F; Fletcher CD; Dal Cin P; De Wever I; Mandahl N; Mitelman F; Rosai J; Rydholm A; Sciot R; Tallini G; Van den Berghe H; Vanni R; Willén H
Genes Chromosomes Cancer; 1998 May; 22(1):16-25. PubMed ID: 9591630
[TBL] [Abstract][Full Text] [Related]
57. Targeted therapies and checkpoint inhibitors in sarcoma.
Vasella M; Gousopoulos E; Guidi M; Storti G; Song SY; Grieb G; Pauli C; Lindenblatt N; Giovanoli P; Kim BS
QJM; 2022 Dec; 115(12):793-805. PubMed ID: 33486519
[TBL] [Abstract][Full Text] [Related]
58. Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model.
Marritt KL; Hildebrand KM; Hildebrand KN; Singla AK; Zemp FJ; Mahoney DJ; Jirik FR; Monument MJ
Front Immunol; 2022; 13():1087991. PubMed ID: 36700206
[TBL] [Abstract][Full Text] [Related]
59. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
Keung EZ; Burgess M; Salazar R; Parra ER; Rodrigues-Canales J; Bolejack V; Van Tine BA; Schuetze SM; Attia S; Riedel RF; Hu J; Okuno SH; Priebat DA; Movva S; Davis LE; Reed DR; Reuben A; Roland CL; Reinke D; Lazar AJ; Wang WL; Wargo JA; Tawbi HA
Clin Cancer Res; 2020 Mar; 26(6):1258-1266. PubMed ID: 31900276
[TBL] [Abstract][Full Text] [Related]
60. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.
He M; Abro B; Kaushal M; Chen L; Chen T; Gondim M; Yan W; Neidich J; Dehner LP; Pfeifer JD
Hum Pathol; 2020 Jun; 100():15-23. PubMed ID: 32387103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
